A
43
2
JWN
72
9
WFC
58
8
HES
49
2
CLX
65
2
NWSA
69
4
MO
47
6
FIS
43
5
WAT
55
11
FCX
44
4
IP
53
3
BLK
47
3
AIG
38
5
WBA
41
3
MHK
25
5
OI
23
3
DLTR
52
8
TROW
37
8
AFL
34
6
USB
50
3
A
43
2
JWN
72
9
WFC
58
8
HES
49
2
CLX
65
2
NWSA
69
4
MO
47
6
FIS
43
5
WAT
55
11
FCX
44
4
IP
53
3
BLK
47
3
AIG
38
5
WBA
41
3
MHK
25
5
OI
23
3
DLTR
52
8
TROW
37
8
AFL
34
6
USB
50
3
Financhill
Back

Cidara Therapeutics 10K Form

Buy
61

CDTX
Cidara Therapeutics

Last Price:
$23.31
Seasonality Move:
12.86%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CDTX News And Ratings

See the #1 stock for the next 7 days that we like better than CDTX

CDTX Financial Statistics

Sales & Book Value

Annual Sales: $63.9M
Cash Flow: $-36.8M
Price / Cash Flow: 0
Annual Sales: $16.41
Price / Book: 2.2

Profitability

EPS (TTM): -25.36000
Net Income (TTM): $-120.7M
Gross Margin: $62.4M
Return on Equity: -443.37%
Return on Assets: -134.09%

Cidara Therapeutics Earnings Forecast

Key Cidara Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for CDTX is 97.62%.
  • The Selling, General & Administrative Expenses for CDTX have been equal to 28.69% of Gross Profit Margin.
  • The Research & Development expenses have been 107.24% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 11 years have been positive in 6 years.

Cidara Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CDTX
CUSIP: 171757
Website: cidara.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.25
Quick Ratio: 4.21

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CDTX Technical Analysis vs Fundamental Analysis

Buy
61
Cidara Therapeutics (CDTX) is a Buy

Is Cidara Therapeutics a Buy or a Sell?